CompletedNCT02252653

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Studying Amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alnylam Pharmaceuticals
Principal Investigator
Jared Gollob, MD
Alnylam Pharmaceuticals
Enrollment
1010 enrolled
Eligibility
18 years · All sexes
Timeline
20142016

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02252653 on ClinicalTrials.gov

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Amyloidosis

← Back to all trials